Don’t let misinformation derail the trachoma elimination programme

[...]data from a 1998-9 western Nepal trial were extrapolated to estimate effectiveness of mass treatment throughout sub-Saharan Africa and South East Asia. [...]costs were assigned for azithromycin purchase using a theoretical price. 2 Azithromycin for trachoma control is donated by the manufacturer. On the basis of analyses that are flawed on both sides of the cost effectiveness equation, Chisholm and colleagues concluded that saving a DALY with mass azithromycin treatment in trachoma endemic areas of sub-Saharan Africa or South East Asia costs more than the per capita gross domestic product of each region.